Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Quoin Pharmaceuticals, Ltd. Sponsored ADR (QNRX : NSDQ)

• Company Description    Quoin Pharmaceuticals is a specialty pharmaceutical company focused on rare and orphan diseases. Quoin Pharmaceuticals, formerly known as Cellect Biotechnology Ltd., is based in Tel Aviv. Number of Employees: 5

• Price / Volume Information    Yesterday's Closing Price: $9.01 Daily Weekly Monthly 20 Day Moving Average: 156,861 shares Shares Outstanding: 0.59 (millions) Market Capitalization: $5.30 (millions) Beta: 1.72 52 Week High: $32.09 52 Week Low: $5.01 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -56.05% -57.20% 12 Week 20.45% 15.46% Year To Date -60.40% -65.39%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 42127 Pleasant Forest Court - Ashburn,VA 20148 USA ph: 703-980-4182 fax: 972-9767-8750 ir@cellectbio.com https://quoinpharma.com

• General Corporate Information    Officers Michael Myers - Chairman and Chief Executive Officer Denise Carter - Chief Operating Officer Gordon Dunn - Chief Financial Officer Joseph Cooper - Director James Culverwell - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 74907L409 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 03/12/26 Share - Related Items Shares Outstanding: 0.59 Most Recent Split Date: 4.00 (0.03:1) Beta: 1.72 Market Capitalization: $5.30 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-6.42 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-25.57 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 03/12/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 59.17% vs. Previous Quarter: -6.85% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 09/30/25 - -334.41 06/30/25 - -210.50 03/31/25 - -148.97 ROA 09/30/25 - -125.15 06/30/25 - -99.41 03/31/25 - -77.23 Current Ratio 09/30/25 - 1.04 06/30/25 - 1.96 03/31/25 - 2.57 Quick Ratio 09/30/25 - 1.04 06/30/25 - 1.96 03/31/25 - 2.57 Operating Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Net Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Pre-Tax Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Book Value 09/30/25 - -2.07 06/30/25 - 4.34 03/31/25 - 10.07 Inventory Turnover 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Equity 09/30/25 - - 06/30/25 - 0.00 03/31/25 - 0.00 Debt-to-Capital 09/30/25 - - 06/30/25 - 0.00 03/31/25 - 0.00

Powered by Zacks Investment Research ©